Echinacea
Echinacea purpurea, E. angustifolia, E. pallida
Evidence Rating
C Moderate
Confidence Level
High
Medium-High
Traditions
Western
Last Updated
2/9/2026
Summary
Echinacea is the most extensively studied herbal immunomodulator, with 20+ RCTs and a Cochrane review. However, the clinical evidence remains frustratingly heterogeneous because different species, plant parts, and preparation types have been tested. European regulators have addressed this by issuing separate monographs for each species/part combination. E. purpurea aerial parts (fresh pressed juice) have the strongest European endorsement and most clinical data. The Cochrane review concludes that some Echinacea products may reduce cold incidence and duration, but the evidence is not definitive. Commission E approved E. purpurea herb, E. purpurea root, and E. pallida root for different indications.
⚠️
Drug Interactions
This herb has significant drug interactions. Do not use if you are taking medications without consulting a healthcare provider first. See detailed interaction information below.
Regulatory Status
| Regulatory Body | Status |
|---|---|
| Commission E (Germany) | âś“ Approved |
| ESCOP (European) | âś“ Approved |
| EMA/HMPC (EU) | âś“ Approved |
Metadata
| Field | Details |
|---|---|
| Common Names (EN) | Purple coneflower (E. purpurea), Narrow-leaved coneflower (E. angustifolia), Pale coneflower (E. pallida) |
| Common Names (DE) | Purpur-Sonnenhut, Schmalblättriger Sonnenhut, Blasser Sonnenhut |
| Botanical Name | Echinacea purpurea (L.) Moench; E. angustifolia DC.; E. pallida (Nutt.) Nutt. |
| Plant Family | Asteraceae (Compositae) |
| Parts Used | Aerial parts (herb) fresh and dried; Root (radix) for all three species |
| Evidence Quality Rating | Moderate — extensive but heterogeneous trial base |
Approved Indications
Commission E (Germany)
| Species/Part | Status | Indication |
|---|---|---|
| E. purpurea herb (aerial parts) | Approved | Supportive therapy for colds and chronic infections of the respiratory tract and lower urinary tract; externally for poorly healing wounds and chronic ulcerations |
| E. purpurea root | Approved | Supportive treatment of influenza-like infections |
| E. pallida root | Approved | Supportive therapy for influenza-like infections |
| E. angustifolia herb and root | Not approved | Commission E issued a negative monograph due to insufficient evidence at the time of evaluation |
ESCOP (European Scientific Cooperative on Phytotherapy)
| Species/Part | Indication |
|---|---|
| E. purpurea herb | Adjunctive treatment and prophylaxis of recurrent infections of the upper respiratory tract (common cold) and urogenital tract |
| E. purpurea root | Adjunctive treatment of recurrent infections of the upper respiratory tract |
| E. pallida root | Adjunctive treatment of the common cold |
EMA/HMPC (European Medicines Agency)
| Species/Part | Category | Indication |
|---|---|---|
| E. purpurea herb (fresh) | Well-established use | Short-term prevention and treatment of common cold |
| E. purpurea herb (fresh) | Traditional use | Small superficial wounds (external) |
| E. purpurea root | Traditional use | Relief of common cold symptoms; relief of spots/pimples in mild acne |
| E. pallida root | Traditional use | Relief of common cold symptoms; externally for pustules in mild acne |
| E. angustifolia root | Traditional use | Relief of common cold symptoms |
Agreement/Disagreement Across Bodies
- High agreement: All bodies concur on use for common cold/URTI symptoms for E. purpurea and E. pallida.
- Key disagreement: Commission E rejected E. angustifolia (1992), while the later HMPC monograph (2012) accepted it under traditional use. This reflects evolving evidence and regulatory frameworks.
- Notable: Only the HMPC grants E. purpurea fresh herb “well-established use” status (the highest tier). All other species/parts are classified as “traditional use.”
Conditions Treated
- Common cold (prevention and treatment) — primary indication across all species
- Upper respiratory tract infections (supportive/adjunctive)
- Lower urinary tract infections (E. purpurea herb only, Commission E/ESCOP)
- Poorly healing superficial wounds (E. purpurea herb, external use)
- Mild acne (E. purpurea root and E. pallida root, traditional use)
- Influenza-like infections (E. purpurea root, E. pallida root)
Mechanism of Action
Active Compounds (Species-Specific)
| Compound Class | E. purpurea | E. angustifolia | E. pallida |
|---|---|---|---|
| Alkylamides | Present (herb + root) | Highest concentration (root) | Low/variable |
| Cichoric acid | Major phenolic | Minor | Minor |
| Echinacoside | Minor | Major phenolic | Major phenolic |
| Polysaccharides | Present (esp. fresh herb) | Present | Present |
| Glycoproteins | Present | Present | Present |
Immunomodulatory Mechanisms
- Alkylamides: Interact with cannabinoid CB2 receptors; modulate TNF-alpha, IL-1, IL-6, and IL-10 production. At low concentrations, they stimulate immune responses; at higher concentrations, they may suppress pro-inflammatory cytokines — suggesting a true immunomodulatory (not purely immunostimulant) effect. [Source: PMC4441164]
- Polysaccharides: Activate macrophages and dendritic cells via TLR4 pathway; enhance phagocytosis. Most abundant in fresh pressed juice preparations. [Source: ESCOP monograph]
- Cichoric acid: Antioxidant; may inhibit hyaluronidase; phagocytosis stimulation. Distinctive to E. purpurea. [Source: Echinacea species review, Barnes 2005]
- Glycoproteins: Enhance cytokine production (TNF-alpha, IL-1, IL-6, interferon)
- Direct antiviral activity: In vitro evidence for activity against influenza, HSV, and rhinoviruses, but clinical relevance uncertain. [UNCERTAIN]
Key Distinction: Immunomodulation vs. Immunostimulation
Modern pharmacological understanding suggests Echinacea preparations (particularly lipophilic/alkylamide-rich extracts) are better described as immunomodulators than simple immunostimulants. The alkylamide fraction can suppress excessive inflammatory responses while enhancing baseline immune surveillance. This has implications for the autoimmune disease contraindication debate. [Source: Review and Assessment of Safety Data, Ardjomand-Woelkart & Bauer 2015]
Clinical Evidence Summary
Cochrane Review (Karsch-Volk et al., 2014)
- 24 double-blind RCTs with 4,631 participants
- Treatment: Some preparations based on E. purpurea aerial parts might be effective for early treatment of colds in adults, but results are not fully consistent
- Prevention: Pooled risk reduction of 17% (RR 0.83, 95% CI 0.75-0.92) across all products, but not significant when restricted to same-product analyses (RR 0.82, 95% CI 0.67-1.02)
- Conclusion: “Echinacea products have not been shown convincingly to provide benefits for treating colds, although it is possible there is a weak benefit from some Echinacea products”
Lancet Meta-Analysis (Shah et al., 2007)
- 14 studies pooled
- Treatment with echinacea reduced cold incidence (OR 0.42, 95% CI 0.25-0.71) and duration (WMD -1.44 days, 95% CI -2.24 to -0.64)
- More favorable conclusions than the Cochrane review, but criticized for including lower-quality studies
Notable Individual Trials
| Trial | Species/Product | n | Key Finding |
|---|---|---|---|
| Jawad et al. 2012 | E. purpurea (Echinaforce) | 755 | 26% fewer cold episodes; 36% fewer recurrent episodes over 4 months |
| Turner et al. 2005 | E. angustifolia root | 399 | No significant effect vs. placebo (negative trial) |
| Barrett et al. 2010 | E. purpurea/angustifolia | 719 | Non-significant trend toward shorter duration (-0.7 days) and milder severity |
| Schulten et al. 2001 | E. purpurea (fresh pressed juice) | 80 | Significant reduction in cold symptoms at onset |
Species-Specific Evidence Summary
- E. purpurea aerial parts (especially fresh pressed juice): Most positive evidence; most studied
- E. purpurea root: Moderate evidence; fewer trials
- E. angustifolia root: Weakest evidence; Turner 2005 negative trial was influential
- E. pallida root: Limited modern trial data; historical Commission E approval based on older German studies
European vs. US/Anglophone Consensus
| Dimension | European Consensus | US/Anglophone Consensus |
|---|---|---|
| Regulatory status | OTC herbal medicine with approved therapeutic indications | Dietary supplement; no therapeutic claims permitted |
| Clinical acceptance | Widely prescribed by German physicians; among top-selling herbal medicines in pharmacies | Popular consumer supplement; most physicians skeptical |
| Species preference | E. purpurea herb (fresh pressed juice) strongly preferred; EchinaCare/Echinaforce are market leaders | E. purpurea and E. angustifolia used interchangeably; species often not specified on labels |
| Evidence interpretation | Commission E/ESCOP/HMPC all affirm efficacy for cold support | NCCIH states “results of studies are mixed” and evidence is “not strong enough to recommend” |
| Preparation standards | Strong emphasis on standardized preparations; fresh pressed juice or defined extraction ratios | Highly variable product quality; many unstandardized products |
| Duration guidance | Limited to 8-10 days (acute) or prophylactic courses with breaks | No standardized guidance |
| Autoimmune contraindication | Commission E originally listed it; now considered questionable by newer research | Still widely cited as absolute contraindication in clinical references |
Safety Profile
Contraindications
- Allergy to Asteraceae (Compositae): Cross-reactivity with ragweed, chrysanthemums, marigolds, daisies. Most significant safety concern. Allergic reactions reported in 1-2% of users.
- Autoimmune disease: Listed by Commission E as contraindication for all Echinacea species. [CONTESTED] — Modern pharmacological evidence suggests lipophilic alkylamide preparations actually suppress rather than stimulate cellular immune responses. Some experts now consider this contraindication outdated. [Source: Ardjomand-Woelkart & Bauer 2015]
- Progressive systemic diseases: TB, multiple sclerosis, collagenoses, AIDS/HIV (Commission E). [CONTESTED] — Based on theoretical immunostimulation concern; limited clinical evidence for harm.
- Children under 12: HMPC restricts oral use to ages 12+. Commission E did not specify age restriction.
Drug Interactions
- Immunosuppressants: Theoretical antagonism (may reduce efficacy of cyclosporine, tacrolimus, etc.)
- CYP enzymes: In vivo pharmacokinetic studies found no significant inhibition of CYP2D6 or CYP3A4 with standardized E. purpurea preparations. CYP1A2 may be mildly inhibited (caffeine clearance reduced ~30%).
- Overall: Drug interaction risk is LOW based on clinical pharmacokinetic data. [Source: Review and Assessment of Safety Data]
Side Effects
- Gastrointestinal: Nausea, stomach pain, diarrhea (uncommon)
- Allergic reactions: Rash, urticaria, angioedema (rare; primarily in Asteraceae-allergic individuals)
- Anaphylaxis: Very rare case reports
Pregnancy/Lactation
- Pregnancy: Possibly safe for short-term use (up to 7 days) during first trimester based on prospective studies of E. purpurea and E. angustifolia. No increase in major malformations observed in cohort studies. [Source: Drugs.com, WebMD] Insufficient data for prolonged use.
- Lactation: Insufficient data. Not recommended by most authorities.
Clinical Dosage
E. purpurea Herb (Fresh Pressed Juice)
- Pressed juice: 6-9 mL daily (e.g., Echinaforce/EchinaCare)
- Dried pressed juice: 176-352 mg daily (equivalent to 3.5-9.8 g fresh herb)
- Duration: Up to 10 days for acute use; prophylactic use with 1-week breaks debated
E. purpurea Root
- Tincture (1:5, 55% ethanol): 1-3 mL three times daily
- Dried root: 1 g three times daily as decoction
- Standardized extract: 300-500 mg three times daily
E. pallida Root
- Tincture: Per Commission E and HMPC, ethanol-based extracts
- Dried root powder: As per manufacturer standardization
E. angustifolia Root
- Tincture (1:5, 45% ethanol): 1-2 mL three times daily (HMPC)
- Liquid extract (1:1, 45% ethanol): 0.25-1 mL three times daily (HMPC)
Key Commercial Products (Europe)
- Echinaforce (A. Vogel/Bioforce): E. purpurea fresh herb + root tincture. Most studied single product.
- EchinaCare: Fresh pressed juice of E. purpurea standardized to 2.4% fructofuranoside
- Esberitox (Schaper & Brummer): Combination product with E. purpurea/pallida + Baptisia + Thuja
- Echinacin (Madaus): E. purpurea pressed juice
Sources
- EMA/HMPC Monographs: E. purpurea herba recens (EMA/HMPC/557979/2013); E. purpurea radix (revision 1); E. pallida radix; E. angustifolia radix (2012)
- Cochrane Review: Karsch-Volk M et al. “Echinacea for preventing and treating the common cold.” Cochrane Database Syst Rev. 2014.
- Shah SA et al. “Evaluation of echinacea for prevention and treatment of the common cold: a meta-analysis.” Lancet Infect Dis. 2007;7(7):473-480.
- Barnes J et al. “Echinacea species: a review of their chemistry, pharmacology and clinical properties.” J Pharm Pharmacol. 2005;57(8):929-954.
- Ardjomand-Woelkart K, Bauer R. “Review and Assessment of Medicinal Safety Data of Orally Used Echinacea Preparations.” Planta Med. 2016;82(1-2):17-31.
- ESCOP Monograph: Echinaceae purpureae herba (Purple Coneflower Herb)
- NCCIH: “Echinacea: Usefulness and Safety” (https://www.nccih.nih.gov/health/echinacea)
Connections
- Andrographis: Alternative URTI treatment with stronger effect sizes but less European regulatory recognition
- Pelargonium: Complementary indication (acute bronchitis vs. common cold)
- Elderberry: Often combined with Echinacea in OTC cold products